MHRA-100028-PIP01-21

Key Facts

PIPS Key Facts
Active Substance
  • tixagevimab (AZD8895)
  • cilgavimab (AZD1061)
Invented Name
Not yet available
PIP Number MHRA-100028-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Infectious diseases
Conditions / Indications
  • Prevention of Coronavirus Disease 2019 (COVID-19)
  • Treatment of Coronavirus Disease 2019 (COVID-19)
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):tixagevimab (AZD8895);cilgavimab (AZD1061).pdf
Published Date 03/11/2021